A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm

Allergan

Status: Completed

Conditions: Cervical Dystonia; Blepharospasm

Treatments: Other: No Intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT02245958

GMA-US-NEU-0271

Details and patient eligibility

About

This study is a retrospective chart review to evaluate the doses of botulinum Type A toxins BOTOX® (onabotulinumtoxinA) and Xeomin® (incobotulinumtoxinA) used for the treatment of Cervical Dystonia and Blepharospasm in clinical practice.

Enrollment: 44 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Confirmed primary diagnosis of idiopathic cervical dystonia or blepharospasm for at least 2 years
• Treatment with Xeomin® and BOTOX® for at least 2 years each.

Exclusion criteria

• Having a neuromuscular junction transmission disorder or taking any medications that could affect neuromuscular junction transmission
• Previous surgical procedure involving bone or muscle for the management of cervical dystonia or blepharospasm.

Trial design

44 participants in 2 patient groups

BOTOX®

Description:

Retrospective chart review of doses of BOTOX® (onabotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.

Treatment:

Other: No Intervention

Xeomin®

Description:

Retrospective chart review of doses of Xeomin® (incobotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.

Treatment:

Other: No Intervention